美國商業資訊

2024-10-09 09:59

Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility

This milestone represents significant progress in Ferring’s manufacturing capabilities to meet anticipated growth in demand for Adstiladrin® (nadofaragene firadenovec-vncg), a gene therapy for people with non-muscle invasive bladder cancer (NMIBC).
With bladder cancer now the ninth most diagnosed cancer around the world 1, securing the global supply of this innovative bladder-sparing treatment is vital.

SAINT-PREX, Switzerland--()--Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin® (nadofaragene firadenovec-vncg). This represents a significant milestone in Ferring’s capabilities and capacity to meet the current and expected growth in demand for this gene therapy for people with non-muscle invasive bladder cancer (NMIBC).

Adstiladrin® (nadofaragene firadenovec-vncg) is approved in the U.S. for adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumours.

“In January this year, we announced full commercial availability of Adstiladrin® in the U.S. We have now embarked on a broad programme of clinical research to enlarge the body of evidence for Adstiladrin® and plan for regulatory submissions in other global markets. Today’s announcement marks an important milestone in ensuring stable and sustainable global supply of Adstiladrin® to meet the anticipated growth in demand,” said Bipin Dalmia, Global Head, Uro-Oncology and Urology Franchise, Ferring Pharmaceuticals.

Armin Metzger, Executive Vice President and Chief Technical Operations Officer, Ferring Pharmaceuticals added, “The continued investment and expansion of our gene therapy manufacturing infrastructure reflects Ferring’s strong commitment to deliver end-to-end solutions for even the most highly complex manufacturing challenges as part of our mission to fulfil the unmet clinical needs for people with bladder cancer.”

According to the International Agency for Research on Cancer, bladder cancer is now the ninth most diagnosed cancer worldwide, previously ranked tenth.1 This rising global incidence underscores the necessity to expand the supply of innovative treatments for this disease.

In addition to this European investment in drug substance, Ferring has further strengthened and diversified its nadofaragene firadenovec-vncg supply chain and is also nearing completion of a new manufacturing facility for drug product at Ferring’s U.S. campus in Parsippany, New Jersey. The bolstering of Ferring’s gene therapy manufacturing capabilities and footprint reinforces its commitment to ensuring the future supply of this therapy for patients.

Located in Kuopio, Finland, the new European manufacturing site features a cutting-edge manufacturing suite, fully integrated with modern technology to produce adenovirus vector-based gene therapy drug substance in large quantities. The 25,000 square metre facility features renewable energy solutions such as waste heat recovery with heat pumps and solar energy, complementing Ferring’s commitment to protect the environment by reducing its negative impact on the planet.

About Adstiladrin® (nadofaragene firadenovec-vncg)
Adstiladrin® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical non-replicating gene therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.2 It is a non-replicating adenovirus vector-based therapy containing the gene interferon alfa-2b, administered locally as a monotherapy by catheter directly into the bladder once every three months. The vector enters the cells of the bladder wall, releasing the active gene and causing the bladder’s cell walls to secrete high and transient local expression of interferon alfa-2b protein, a naturally occurring protein the body uses to fight cancer. This approach essentially turns the bladder wall cells into interferon microfactories, enhancing the body’s own natural defences against the cancer.3

Adstiladrin® (nadofaragene firadenovec-vncg) has been studied in a clinical trial programme that includes 157 patients with high-grade, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and did not see benefit from additional BCG treatment (full inclusion criteria published on clinicaltrials.gov: NCT02773849).3

About non-muscle invasive bladder cancer (NMIBC)
NMIBC is a form of bladder cancer in which the tumour is not invading into or beyond the muscularis propia.4 Bladder cancer is the 9th most common cancer worldwide, with 614,298 new cases reported in 2022.5 75% of bladder cancers present as NMIBC.6 In patients with high-risk NMIBC, intravesical BCG remains the first-line standard of care.7 Current treatment options for BCG-unresponsive patients are very limited outside of radical cystectomy (partial or complete removal of the bladder).7 In a patient choice experiment to determine preferred treatment options for NMIBC, 89% of patients never selected radical cystectomy as their preferred option; patients were willing to accept a 43.8% increased risk of progression and a 66.1% increase in the risk of serious side effects to increase the time to radical cystectomy from 1 year to 6 years.8

About gene therapy and the manufacturing process
Gene therapies aim to treat, prevent, or cure diseases by modifying or manipulating gene expression or altering the biological properties of living cells. 9 The concept involves techniques like adding new copies of a gene or replacing faulty genes with healthy ones.10 Over the decades, gene therapies have been applied to inherited genetic diseases, cancers, and other disorders. Viral vectors, bacterial vectors, plasmid DNA, human gene editing, and patient-derived cellular gene therapies are various forms of gene therapy.9 Viral vectors are particularly significant due to their high transduction efficiency and stable expression, offering potentially curative treatments with fewer applications.11 Successful applications include treatments for bladder cancer, leukaemia, lymphoma, haemophilia, certain neurological disorders, retinal diseases, and metabolic disorders.12-18

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which markets its medicines in over 100 countries.

Learn more at www.ferring.com, or connect with us on LinkedInInstagramYouTubeFacebook and X(Twitter).

© 2024 Ferring. Ferring and the Ferring Pharmaceuticals logo are trademarks of the Ferring group of companies.

References:

  1. International Agency for Research on Cancer. GLOBOCAN 2022 factsheet. Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf [Accessed July 2024].
  2. U.S. FDA. ADSTILADRIN. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/adstiladrin [Accessed July 2024].
  3. ClinicalTrials.gov. ADSTILADRIN in patients with high grade, Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC). Gov Identifier: NCT02773849. Available from: https://clinicaltrials.gov/ct2/show/NCT02773849 [Accessed July 2024].
  4. Matulewicz RS, Steinberg GD. Non-muscle-invasive bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies. Rev Urol. 2020 Jul; 22(2):43-51.
  5. International Agency for Research on Cancer. Cancer Today. Available from: https://gco.iarc.fr/today/en/dataviz/bars?mode=cancer&group_populations=1&key=total [Accessed July 2024].
  6. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013 May; 63(2):234-41.
  7. Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 Nov 27; 22:107-17.
  8. Collacott H, Krucien N, Heidenreich S, Catto JWF, Ghatnekar O. Patient Preferences for Treatment of Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: A Cross-country Choice Experiment. Eur Urol Open Sci. 2023 Jan 31;49:92-99.
  9. U.S. FDA. What is gene therapy? Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy [Accessed July 2024].
  10. NIH. Gene Therapy. Available from: https://www.genome.gov/genetics-glossary/Gene-Therapy [Accessed July 2024].
  11. Braendstrup P, Levine BL, Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy. 2020 Feb;22(2):57-69
  12. Munis AM. Gene therapy applications of non-human lentiviral vectors. Viruses. 2020 Sep 29; 12:1106. doi: 10.3390/v12101106.
  13. Miyake H, et al. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Neoplasia. 2005 Feb; 7(2): 171-9. doi:10.1593/neo.04478.
  14. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor t cells for sustained remissions in leukemia. New England Journal of Medicine. 2014 Oct 16; 371(16), 1507-1517.
  15. Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. New England Journal of Medicine. 2014 Nov 20; 371(21), 1994-2004.
  16. Bankiewicz, K. S., Eberling, J. L., Kohutnicka, M., et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys: In vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Experimental Neurology. 2000 Jul; 164(1), 2-14.
  17. Russell, S., Bennett, J., Wellman, J. A., et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. The Lancet. 2017 Aug 26; 390(10097), 849-860.
  18. Seker Yilmaz B, Gissen P. Genetic therapy approaches for ornithine transcarbamylase deficiency. Biomedicines. 2023 Aug 8; 11(8):2227. doi: 10.3390/biomedicines11082227.

Contacts

Matthew Worrall
Director of Corporate Communications and Public Affairs, Ferring Pharmaceuticals
Matthew.worrall@ferring.com

Matt Handcock
Senior Account Manager, Syneos Health Communications
Matt.handcock@syneoshealth.com

【你點睇?】美國總統特朗普批評烏克蘭總統澤連斯基是「一位未經選舉的獨裁者」,俄烏戰爭早應停止。你是否認同特朗普的說法?► 立即投票

人氣文章
最近7天
1
高息定存 | 一周高息合集,減息預期降溫,銀行3個月最高5.68厘,6個月3.55厘
2
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
3
【FOCUS】悟空、哪吒、DeepSeek,如何啟示香港
4
民營企業座談會 | 習近平在京出席民營企業座談會
5
神州經脈 | 習近平:經濟政策不會變,民企大顯身手正當其時
6
港股 | 蕭猷華:恒指升勢可持續?
7
譚仔 | 譚仔國際日資大股東溢價76%建議私有化今復牌,上市不足三年半
8
神州經脈 | 中國減持美債,螞蟻入局具身智能,70城樓價向好
9
AI | 追捧DeepSeek,全球對沖基金棄印度投中國
10
阿里預測 | 阿里第三財季料少賺逾2%,淘天表現改善變現力提升
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
3
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
4
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
5
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
6
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
7
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
8
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
9
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
10
一本萬利 | 2025年的五個「勿」(有片)
11
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
12
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
13
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
14
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
15
洪灝專訪 | 淘寶衝擊巨大,港樓價未反映大周期拐點(有片)
16
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
17
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
18
高息定存 | 一周高息合集,減息預期降溫,銀行3個月最高5.68厘,6個月3.55厘
19
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
20
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
21
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
22
【FOCUS】悟空、哪吒、DeepSeek,如何啟示香港
23
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
24
【FOCUS】侵侵呼籲全球「降息」,日銀祭18年最激進加息
25
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
26
彭博亞洲20大富裕家族,香港5大家族上榜,新地郭氏排名最高,無李嘉誠李兆基?
27
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
28
高息定存 | 信銀國際12個月港元定存高達3.5厘
29
神州經脈 | 特朗普或與華討論關稅,人民幣大漲,滬指連升兩周
30
David Webb:因病情惡化,將有序結束個人財經網站
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老